



ABIVAX to participate in the European Small-Cap Event in Paris on April 11-12, 2016

Paris, March 31, 2016 – ABIVAX (Euronext Paris : FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it will participate in the European Small-Cap Event, to be held on April 11 and 12, 2016, at the Pullman Hotel in Paris.

At the conference, Professor Hartmut Ehrlich, M.D., CEO of ABIVAX, and Alain Chevallier, CFO, will present ABIVAX's strategy and most recent news to investors in one-on-one meetings.

About ABIVAX (www.ABIVAX.com)

ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and therapeutic vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis

B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.

Follow us on Twitter @ABIVAX

Contacts

Investor Relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 09 63

Citigate Dewe Rogerson

Lucie Larguier
abivax@citigate.fr
+33 1 53 32 84 75

LifeSci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations

ALIZE RP
Caroline Carmagnol et Margaux Pronost
abivax@alizerp.com
+33 6 64 18 99 59 / + 33 1 44 54 36 64